Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ionis Pharmaceuticals Q4 2025 Earnings Call - Olezarsen phase 3 win positions company for blockbuster sHTG launch
Ionis closed 2025 as a transformed commercial-stage company, driven by two independent launches and a string of pivotal data readouts. TRYNGOLZA (FCS) and DAWNZERA (HAE) gained early commercial tracti...
- Olezarsen phase 3 (CORE and CORE2) showed up to 72% placebo-adjusted fasting triglyceride reductions at six months and an 85% adjudicated reduction in acute pancreatitis events, a first in this population.
- Ionis submitted an sNDA for Olezarsen at the end of 2025, has Breakthrough Therapy designation, and says it is launch-ready by June, though guidance assumes a standard FDA review (implying a later, Q4 launch unless priority review is granted).
- Olezarsen clinical impact includes an NNT of 4 to prevent one acute pancreatitis attack in the highest-risk subgroup, a striking metric management used to argue the drug's value.
- +12 more takeaways
Taboola Q4 2025 Earnings Call - Realize Shows Early Traction, Guidance Stays Conservative
Taboola closed 2025 with modest acceleration driven by its Realize advertising platform, beatings its own ex-TAC and margin targets while returning capital aggressively via share repurchases. The comp...
- Realize is the strategic focal point, credited with early signs of acceleration in advertiser spend and retention after one year of rollout.
- Full year 2025 ex-TAC Gross Profit was about $714 million, up roughly 7% year-over-year, driven by Realize and Taboola News.
- Management highlighted adjusted EBITDA growth but reported inconsistent figures on the call, CFO cited full year Adjusted EBITDA of $215.5 million (30% margin), while the CEO referenced $260 million; investors should note the discrepancy.
- +12 more takeaways
Tanger Inc. Q4 2025 Earnings Call - Leasing Momentum and a Reworked Balance Sheet Give the Company Optionality
Tanger closed 2025 with operational momentum and a materially improved balance sheet. Record leasing volume, a 98.1% year-end occupancy rate, and 4.3% Same Center NOI growth powered Core FFO of $0.63 ...
- Q4 Core FFO was $0.63 per share, up 16.7% year over year; full year Core FFO was $2.33, up 9.4% from 2024.
- Same Center NOI grew 4.3% in 2025, driven by leasing, recoveries, and contribution from recent acquisitions; 2026 guidance calls for 2.25% to 4.25% growth.
- Record leasing volume exceeded 3 million square feet for 2025, with occupancy finishing the year at 98.1%, a 70 basis point sequential increase.
- +12 more takeaways
Archrock Q4 2025 Earnings Call - Durable cash flow, lower leverage, and disciplined reinvestment in compression
Archrock closed 2025 with a punchy set of results: double-digit operating horsepower growth, sustained >95% fleet utilization for 11 consecutive quarters, and free cash flow that let the company pay d...
- 2025 financials were strong: Adjusted EPS rose 68% year over year, and Adjusted EBITDA increased 51% year over year.
- Reported full-year 2025 Adjusted EBITDA was $901 million, but excluding discrete items (tax settlements and asset-sale gains) underlying Adjusted EBITDA was $846 million.
- 2026 Adjusted EBITDA guidance is $865 million to $915 million, with a midpoint of $890 million.
- +12 more takeaways
Unisys Q4 2025 Earnings Call - LNS-led profit rebound and pension derisking set stage for AI-driven growth
Unisys closed 2025 with a clear bifurcation: strong license and support (LNS) performance lifted margins and cash generation, while XLNS (non‑LNS) businesses faced headwinds from PC refresh delays, pu...
- Q4 2025 revenue was $575 million, up 5.3% year-over-year as reported, full-year revenue was $1.95 billion, down 2.9% as reported.
- LNS (license and support) was the standout: Q4 LNS revenue $186 million, up 19.8% year-over-year; full-year LNS revenue $428 million, exceeding revised expectations.
- Management expects 2026 LNS revenue of $415 million, with LNS margin around 70%, and targets roughly $400 million average LNS per year in 2027-2028.
- +12 more takeaways
Bloomin' Brands, Inc. Q4 2025 Earnings Call - Outback turnaround shows early traffic wins on new steak lineup, but margins and beef inflation cap upside
Bloomin' Brands spent Q4 2025 proving a thesis rather than printing a breakout quarter. Revenue held steady at $975 million and U.S. comps were flat, but management points to clear early progress at O...
- Q4 total revenue was $975 million, essentially flat versus $972 million a year ago.
- U.S. comparable restaurant sales were flat in Q4, with U.S. traffic up 50 basis points; comps trailed the Black Box casual dining benchmark by 40 bps but narrowed the gap significantly quarter-over-quarter.
- Outback comp sales were down 60 bps in Q4, but Outback traffic was up 90 bps — the first positive traffic quarter for the brand since Q4 2021.
- +16 more takeaways
APi Group Q4 2025 Earnings Call - Record $836M free cash flow and margin momentum as data centers lift growth
APi delivered a tidy set of milestones for 2025: double-digit revenue growth, expanding margins and record free cash flow. Management hit the outgoing 13/60/80 targets—13.2% adjusted EBITDA margin and...
- APi reported full year 2025 net revenues up 13% year over year, with ~8% organic growth for the year.
- Q4 2025 net revenues were $2.12 billion, a 13.8% increase versus prior year; Q4 organic growth was 11.1%.
- Adjusted EBITDA margin for full year 2025 came in at 13.2%, surpassing the 13% target; Q4 adjusted EBITDA margin was 13.9% (+90 bps YoY).
- +12 more takeaways
Ironwood Pharmaceuticals Q4 2025 Earnings Call - LINZESS Set to Reclaim Blockbuster Status in 2026
Ironwood closes 2025 with a clear, if pragmatic, playbook: lean on LINZESS to fund the next act while running a confirmatory Phase 3 for apraglutide. LINZESS posted $865 million in U.S. net sales for ...
- LINZESS U.S. net sales for 2025 totaled $865 million, with full-year prescription demand growth of 11% and new-to-brand volume growth noted at 8% year-over-year.
- Management lowered LINZESS list price effective January 1, 2026 to address healthcare dynamics, preserve patient access, and remove the inflationary component of statutory rebates.
- Ironwood expects LINZESS U.S. net sales of $1.125 billion to $1.175 billion in 2026, a greater than 30% year-over-year increase driven mainly by improved net price and low single-digit demand growth.
- +12 more takeaways
CS DISCO Q4 FY2025 Earnings Call - GenAI Adoption and Per-GB Pricing Pave Path to Profitability
DISCO closed FY2025 with accelerating software growth driven by broad adoption of its Cecilia generative AI and Auto Review products, and management launched a material commercial reset that bundles C...
- Q4 total revenue $41.2M, up 11% year-over-year; Q4 software revenue $35.1M, up 14% year-over-year.
- FY2025 total revenue $156.8M, up 8% year-over-year; FY2025 software revenue $134M, up 12% year-over-year.
- Adjusted EBITDA improved to negative $10.2M for FY2025, a margin of negative 7%, versus negative 13% in FY2024; Q4 Adjusted EBITDA was negative $2.2M, a negative 5% margin.
- +16 more takeaways
Astec Industries Fourth Quarter and Full Year 2025 Earnings Call - Backlog, M&A and Parts Push Fuel Ambitious $170M-$190M 2026 EBITDA Guide
Astec closed 2025 with a stronger footing than many expected, reporting record Q4 revenue of $400.6 million and full-year net sales up 8.1% driven by a mix of organic strength and two strategic acquis...
- Record Q4 net sales of $400.6 million, contributing to full-year net sales growth of 8.1% driven by both organic activity and acquisitions.
- Full-year Adjusted EBITDA of $140.7 million, at the high end of guidance, with consolidated Adjusted EBITDA margin rising 140 basis points to 10% year over year.
- Q4 Adjusted EBITDA was $44.7 million, with a Q4 Adjusted EBITDA margin of 11.2%.
- +12 more takeaways